TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31282575

Group type: EXPERIMENTAL
Intervention: Sniffing position using channelled (KingVision®) videolaryngoscope
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral position using non‐channelled (C‐MAC®) videolaryngoscope
Number of subjects: 0
Study: 28716519

Group type: EXPERIMENTAL
Intervention: Simvastatin plus Ezetimibe
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 0
Study: 26944728

Group type: EXPERIMENTAL
Intervention: Transanal approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparoscopic approach
Number of subjects: 100
Study: 24713413

Group type: EXPERIMENTAL
Intervention: E(2)V/DNG
Number of subjects: 507

Group type: COMPARATOR
Intervention: EE/LNG
Number of subjects: 507
Study: 22723578

Group type: EXPERIMENTAL
Intervention: Insulin plus metformin (INS group)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Triple oral therapy (TOT group)
Number of subjects: 58
Study: 21171670

Group type: EXPERIMENTAL
Intervention: Lesogaberan (150 mg twice daily)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Esomeprazole (40 mg once daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of lesogaberan and esomeprazole
Number of subjects: 30
Study: 18487004

Group type: EXPERIMENTAL
Intervention: Analyze Later
Number of subjects: 13239

Group type: COMPARATOR
Intervention: Analyze Early
Number of subjects: 13239
Study: 15781539

Group type: EXPERIMENTAL
Intervention: 0.33% bupivacaine
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.33% ropivacaine
Number of subjects: 42
Study: 14599331

Group type: EXPERIMENTAL
Intervention: Internet-based videoconferencing (n=24)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard classroom procedure (n=15)
Number of subjects: 39
Study: 9703606

Group type: EXPERIMENTAL
Intervention: Smaller access laparoscopic inguinal hernia repair (LH)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard laparoscopic inguinal hernia repair (LH)
Number of subjects: 40
Study: 7493230

Group type: EXPERIMENTAL
Intervention: Primary argon laser trabeculoplasty
Number of subjects: 82

Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 82
Study: 1695070

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine (300 mg twice daily)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg or 300 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 686240

Group type: EXPERIMENTAL
Intervention: 150 mg of tinidazole twice daily for 7 days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Single dose of 2,000 mg of tinidazole
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both dosages of tinidazole
Number of subjects: 45
Study: 30950715

Group type: EXPERIMENTAL
Intervention: Aquablation in WATER trial (30cc to 80cc prostates)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Aquablation in WATER II trial (80cc to 150cc prostates)
Number of subjects: 217
Study: 28203695

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (2 × 30 minutes/week)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Reference group (lectures)
Number of subjects: 116
Study: 25469723

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MOX) 400 mg once daily for 7 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo once daily for 7 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MOX)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23683444

Group type: EXPERIMENTAL
Intervention: Esmolol 0.5mg.kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5mg.kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fentanyl 2μg.kg(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (Saline 5mL)
Number of subjects: 80
Study: 22000683

Group type: EXPERIMENTAL
Intervention: Training and support programme in primary care practices
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control practices (no training and support programme)
Number of subjects: 51
Study: 18471084

Group type: EXPERIMENTAL
Intervention: PfMSP5 or PvMSP5 immunoglobulin (Ig)G
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: PfMSP5 or PvMSP5 immunoglobulin (Ig)M
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: IgG responses for PfMSP5
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: IgG responses for PvMSP5
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Cross-reactivity in dual-positive responders
Number of subjects: 340

Group type: COMPARATOR
Intervention: Magnitude, frequency, or subclass of PfMSP5 or PvMSP5 IgG antibodies
Number of subjects: 340

Group type: COMPARATOR
Intervention: Antibody responses and therapeutic response
Number of subjects: 340
Study: 16546905

Group type: EXPERIMENTAL
Intervention: Active exposure to mobile phone emissions for 30 min (0.25 W average power)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Sham exposure (control)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Active exposure to mobile phone emissions
Number of subjects: 55
Study: 12761586

Group type: EXPERIMENTAL
Intervention: 4% BET toothpaste
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1% SLS and 4% BET toothpaste
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 1% SLS toothpaste
Number of subjects: 27

Group type: COMPARATOR
Intervention: Reference toothpaste (neither SLS nor BET)
Number of subjects: 27
Study: 11171280

Group type: EXPERIMENTAL
Intervention: Methionine (0.1 mg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Methionine plus Vitamin C
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9505736

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopy (INVOS 3100)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Jugular bulb oximetry
Number of subjects: 10
Study: 7519691

Group type: EXPERIMENTAL
Intervention: Trandolapril, 2 mg o.d.
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 3174757

Group type: EXPERIMENTAL
Intervention: 20% nitrous oxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7957523

Group type: COMPARATOR
Intervention: Flosequinan (100 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Xamoterol (200 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Combined treatment (flosequinan + xamoterol)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Xamoterol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Combined treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Flosequinan
Number of subjects: 8
Study: 384643

Group type: EXPERIMENTAL
Intervention: Cefaclor (250 mg orally every eight hours for ten days)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Amoxicillin (250 mg orally every eight hours for ten days)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cefaclor and Amoxicillin
Number of subjects: 51
Study: 29374998

Group type: EXPERIMENTAL
Intervention: Near-death experiences (NDEs) reported by burn survivors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Counseling and education for health professionals about NDEs
Number of subjects: 0
Study: 30103793

Group type: COMPARATOR
Intervention: Tax message
Number of subjects: 21

Group type: COMPARATOR
Intervention: Subsidy message
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: No message (control)
Number of subjects: 21
Study: 26296651

Group type: EXPERIMENTAL
Intervention: Prenatal health education intervention
Number of subjects: 1181

Group type: COMPARATOR
Intervention: Usual clinical care (control)
Number of subjects: 1181
Study: 23937319

Group type: EXPERIMENTAL
Intervention: CC + EV (6 mg/day on day 10-14)
Number of subjects: 34

Group type: COMPARATOR
Intervention: CC + placebo (vitamin B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CC + EV
Number of subjects: 34
Study: 22364776

Group type: EXPERIMENTAL
Intervention: Osmotic-release oral system methylphenidate (OROS-MPH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19027340

Group type: EXPERIMENTAL
Intervention: Transverse friction massage (TFM)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (rest period)
Number of subjects: 28
Study: 17877850

Group type: EXPERIMENTAL
Intervention: Differences in work goals and information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Similarities in one respect (either work goals or information)
Number of subjects: 0
Study: 15151838

Group type: EXPERIMENTAL
Intervention: V+D+M treatment protocol (levofloxacin, pasiniazide, M. Vaccae)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: V+D+M treatment protocol
Number of subjects: 97
Study: 12492253

Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10 mg dexamethasone combined with 60 mg lidocaine
Number of subjects: 40
Study: 11273108

Group type: EXPERIMENTAL
Intervention: Conventional carbamazepine (200 mg thrice a day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Slow-release carbamazepine formulation (200 mg thrice a day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Conventional carbamazepine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Slow-release carbamazepine
Number of subjects: 20
Study: 7926243

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 10
Study: 2571320

Group type: EXPERIMENTAL
Intervention: Terfenadine (180 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Terfenadine (180 mg) plus Flurbiprofen (100 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg)
Number of subjects: 9
Study: 1206610

Group type: EXPERIMENTAL
Intervention: Problem-solving training groups (8 sessions)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Play-reading groups (placebo condition)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 41
Study: 31012824

Group type: EXPERIMENTAL
Intervention: Cryotherapy (ice pack)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (room temperature sand pack)
Number of subjects: 16
Study: 29253401

Group type: EXPERIMENTAL
Intervention: 20% price discount on fruit, vegetables, water, and artificially sweetened soft drinks for 24 weeks
Number of subjects: 20
Study: 25549577

Group type: EXPERIMENTAL
Intervention: Fascia suture technique (FST)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prostar technique
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: FST
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prostar
Number of subjects: 100
Study: 24103511

Group type: EXPERIMENTAL
Intervention: Standardized individual nutritional therapy (counseling by a dietitian, food fortification, oral nutritional supplements if required)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 58
Study: 21545947

Group type: EXPERIMENTAL
Intervention: Rolofylline 30 mg/day for up to 3 days
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Intravenous placebo for up to 3 days
Number of subjects: 2033

Group type: EXPERIMENTAL
Intervention: Rolofylline 30 mg/day
Number of subjects: 2033

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 2033
Study: 19466436

Group type: EXPERIMENTAL
Intervention: Hydrocarbon cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated skin
Number of subjects: 0
Study: 16789458

Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical interventions
Number of subjects: 0
Study: 15288334

Group type: EXPERIMENTAL
Intervention: $20 incentive
Number of subjects: 95

Group type: COMPARATOR
Intervention: No incentive
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Immediate preparation
Number of subjects: 95

Group type: COMPARATOR
Intervention: Delayed preparation
Number of subjects: 95
Study: 11040722

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9262415

Group type: EXPERIMENTAL
Intervention: Single matching nontarget
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single nonmatching nontarget
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cued location with precue
Number of subjects: 0
Study: 8245877

Group type: EXPERIMENTAL
Intervention: Ganciclovir (5 mg/kg/IV/q 12 hours for the first 14 days post-LT) followed by acyclovir (800 mg/po/qid for 14 weeks)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg/po/qid for 16 weeks, starting immediately post-LT)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Matched historical controls
Number of subjects: 218
Study: 3516669

Group type: EXPERIMENTAL
Intervention: Milacemide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Milacemide (in patients aged ≤ 25 years)
Number of subjects: 30
Study: 31894491

Group type: EXPERIMENTAL
Intervention: Teriparatide followed by alendronate (once-weekly subcutaneous injections of teriparatide 56.5 μg for 72 weeks followed by alendronate for 48 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alendronate monotherapy (alendronate for 120 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teriparatide followed by alendronate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alendronate monotherapy
Number of subjects: 0
Study: 31032601

Group type: EXPERIMENTAL
Intervention: Successful percutaneous treatment of CTO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CTO-PCI (percutaneous coronary intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unsuccessful revascularization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 0
Study: 27914274

Group type: EXPERIMENTAL
Intervention: Vaginal prostaglandin E2 gel (Prepidil®, dinoprostone) before labor (PGE group, n=90)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No treatment (unmedicated group, n=90)
Number of subjects: 180
Study: 25643895

Group type: EXPERIMENTAL
Intervention: Cerebral hemorrhage (CH) in women
Number of subjects: 13788

Group type: EXPERIMENTAL
Intervention: Cerebral hemorrhage (CH) in women with JCS0 (alert)
Number of subjects: 13788

Group type: EXPERIMENTAL
Intervention: Cerebral hemorrhage (CH) in women with JCS1 (disoriented but awake)
Number of subjects: 13788

Group type: EXPERIMENTAL
Intervention: Cerebral hemorrhage (CH) in women with JCS2 (arousable with stimulation)
Number of subjects: 13788

Group type: EXPERIMENTAL
Intervention: Cerebral hemorrhage (CH) in women with JCS3 (unarousable)
Number of subjects: 13788

Group type: EXPERIMENTAL
Intervention: Cerebral infarction (CI) in women with JCS3 (unarousable)
Number of subjects: 13788
Study: 23112266

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 126

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 126
Study: 21434780

Group type: EXPERIMENTAL
Intervention: Chungkookjang (CKJ) supplementation (26 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 19015590

Group type: EXPERIMENTAL
Intervention: Candesartan (ARB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nifedipine (CCB)
Number of subjects: 0
Study: 16611280

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 90
Study: 12806228

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care (SSC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional holding (TH)
Number of subjects: 100
Study: 11186596

Group type: EXPERIMENTAL
Intervention: Combined walking and conversation treatment
Number of subjects: 65

Group type: COMPARATOR
Intervention: Assisted walking
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conversation-only intervention
Number of subjects: 65
Study: 8679356

Group type: EXPERIMENTAL
Intervention: Fentanyl 3 micrograms kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2068601

Group type: EXPERIMENTAL
Intervention: Health Belief Model Intervention
Number of subjects: 842

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 842
Study: 6307178

Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg daily for 3 consecutive days every 2 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (polychemotherapy and radiotherapy of standard dose or low dose)
Number of subjects: 61
Study: 31335776

Group type: EXPERIMENTAL
Intervention: Immediate Everolimus (EVR)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Delayed Everolimus (EVR)
Number of subjects: 394
Study: 31236143

Group type: EXPERIMENTAL
Intervention: suPAR group (7,905 patients)
Number of subjects: 16801

Group type: COMPARATOR
Intervention: suPAR group (discharged within 24 hours)
Number of subjects: 16801
Study: 26183594

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Probiotic (for patients with pre-existing abdominal pain)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo (for patients with pre-existing abdominal pain)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 320
Study: 25925690

Group type: EXPERIMENTAL
Intervention: NBI with SD colonoscopy
Number of subjects: 431

Group type: COMPARATOR
Intervention: WLI with SD colonoscopy
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: NBI with WA colonoscopy
Number of subjects: 431

Group type: COMPARATOR
Intervention: WLI with WA colonoscopy
Number of subjects: 431
Study: 23499231

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT) with body image component using Virtual Reality techniques
Number of subjects: 34

Group type: COMPARATOR
Intervention: Cognitive Behavioral Treatment (CBT) without body image component
Number of subjects: 34
Study: 22164810

Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (relaxation with a therapist holding feet)
Number of subjects: 26
Study: 19937119

Group type: EXPERIMENTAL
Intervention: 5-module intervention session
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 108
Study: 16374671

Group type: EXPERIMENTAL
Intervention: Participants told they were taking a drug (unconditional expectations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants told they may or may not be receiving a drug (conditional expectations)
Number of subjects: 0
Study: 15498055

Group type: EXPERIMENTAL
Intervention: Tropicamide 0.5% and phenylephrine 0.5% (regimen I)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Tropicamide 1.0% and cyclopentolate 1.0% (regimen II)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Atropine 1.0% (regimen III)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Manifest SE
Number of subjects: 25

Group type: COMPARATOR
Intervention: Regimen I vs Regimen II in children without strabismus
Number of subjects: 25

Group type: COMPARATOR
Intervention: Regimen I vs Regimen II in children older than 5 years
Number of subjects: 25
Study: 10647664

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study: 7908244

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg (5-10 years) or 20 mg (11-15 years) once daily before breakfast
Number of subjects: 40

Group type: COMPARATOR
Intervention: Terfenadine
Number of subjects: 40
Study: 3530644

Group type: EXPERIMENTAL
Intervention: Five bronchodilator drugs (specific drugs not mentioned)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nebulizer delivery method
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Metered-dose inhalers delivery method
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of medication and delivery method
Number of subjects: 10
Study: 30588922

Group type: COMPARATOR
Intervention: Nitroglycerin (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Remifentanil (group B)
Number of subjects: 30
Study: 27489153

Group type: EXPERIMENTAL
Intervention: One-to-one volunteer support for patients with psychosis over a 1-year period, with weekly meetings and engagement in social and recreational activities.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual with a booklet detailing locally available social activities.
Number of subjects: 0
Study: 25041486

Group type: EXPERIMENTAL
Intervention: Ilaprazole 10 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ilaprazole 20 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ilaprazole 40 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 40
Study: 22302034

Group type: EXPERIMENTAL
Intervention: γ-secretase inhibitor LY450139
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: γ-secretase modulator E2012
Number of subjects: 0
Study: 20727128

Group type: EXPERIMENTAL
Intervention: Carotid IMT measurement using B-mode ultrasound and MIA vascular tools
Number of subjects: 60
Study: 18448989

Group type: EXPERIMENTAL
Intervention: Platelet gel supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no platelet gel)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tibia segment with platelet gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tibia segment control
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Humerus segment with platelet gel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Humerus segment control
Number of subjects: 20
Study: 15802445

Group type: EXPERIMENTAL
Intervention: Coil placement in the gastroduodenal artery and around the infusion catheter tip (Group A)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No coil placement (Group B)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 78
Study: 12776031

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 100
Study: 10488295

Group type: EXPERIMENTAL
Intervention: 25 micrograms ITF (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 37.5 micrograms ITF (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 50 micrograms ITF (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60